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Abstract
Background: MDR Mycobacterium tuberculosis is the major cause of treatment failure in
tuberculosis patients, especially in immunosuppressed. We described a young polymyositis patient
on immunosuppressive therapy who was started with antituberculosis therapy as a susceptible
strain of M. tuberculosis was isolated from a single cutaneous abscess in his neck and from regional
lymph nodes.
Case presentation: He had non-reactive miliary tuberculosis and multiple cutaneous abscesses
6 months later with the same strain, which was resistant this time to 9 antituberculosis drugs. We
described clinical presentation, radiological and laboratory work-up, treatment and follow-up as
the patient was cured after 1.5 years with 6 antituberculosis drugs.
Conclusion: To our knowledge, this is the first reported case where an immunosuppressed
patient with suggestive exogenous reinfection within 6 months with the same but MDR strain of
M. tuberculosis was cured. Intense management and regular follow up were important since the
patient was a potent source of MDR M. tuberculosis infection and there was limited choice for
therapy.
Background
World Health Organization published the Global Tuber-
culosis Control Report (2003) on 'World Tuberculosis
Day' where India is ranked number one in the world for
high incidence of smear positive cases of pulmonary
(about 0.9 million) and extrapulmonary TB (about 0.2
million) every year [1]. Undoubtedly, TB itself has
reemerged in India as a serious problem since 1985 with
the advent of HIV/AIDS [2]. However, cutaneous TB is still
rare in countries like India (0.10%), Hong Kong (0.07%)
and Madrid (0.14%) [2] and it manifests either as a true
bacterial invasion or as a tuberculid (hypersensitivity reac-
tion) with primary focus elsewhere. Evidences of bacterial
invasion are found in lupus vulgaris, the most common
manifestation (55%) in patients with cutaneous TB
(1975–95) in northern India [2], primary chancre, tuber-
culous verrucosa cutis, scrofuloderma, tuberculous cutis
orificialis and tuberculous cutis miliaris disseminates [3]
whereas erythema induratum (Bazin disease) and lichen
scrofulosorum are tuberculid lesions [2]. Moreover,
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rather than M. tuberculosis are the most common etiologi-
cal agents for cutaneous TB in HIV/AIDS and other immu-
nocompromised patients.
WHO defines acquired drug resistance as the isolation of
drug-resistant M. tuberculosis from a patient who has been
treated for TB for 1 month or longer [4] and primary drug
resistance as the isolation of drug-resistant strain from a
patient without a history of previous treatment. The selec-
tion of M. tuberculosis with mutations conferring resist-
ance to antitubercular drugs may result from poor
management including the prescription of incorrect regi-
mens and non-compliance with treatment.
We report a rare case of reinfection with same but MDR M.
tuberculosis in a polymyositis patient on immunosuppres-
sive therapy resulting in multiple cutaneous abscesses and
miliary TB.
Case Presentation
A 23-year-old polymyositis patient with suggestive clinical
symptoms, muscle biopsy, enzyme assay, needle EMG
and NCV test was on immunosuppressive drugs such as
corticosteroids at 1 mg/kg/day for 3 to 4 weeks, tapered
gradually over a period of 10 weeks to 1 mg/kg every alter-
nate days and methotrexate at 7.5 mg weekly with gradual
increase to 25 mg weekly for a period of 1 year when he
experienced slightly improved muscle power.
He had single cutaneous abscess 6 months later on the
right side of the neck with no sinus formation and cervical
and axillary lymphadenopathy. He was HIV-negative with
normal CXR and there was no AFB in three consecutive
(spot-early morning-spot) sputum samples (induced in
two occasions). However, the aspirated pus from cutane-
ous abscess and biopsy of the axillary lymph node showed
plenty of M. tuberculosis as culture was confirmed by
niacin and nitrate reduction tests, rapid bacteriophage
assay (FAST Plaque Tuberculosis kit, BIOTEC Laboratories
Ltd, UK) and RFLP analysis (figure 1) using species-spe-
cific probes for devR (Differentially expressed virulent
gene) [5].
In RFLP analysis, the devR gene (Gene bank nucleotide
sequence accession no. U22037) encodes a response reg-
ulator that is part of a two-component signal transduction
system of M. tuberculosis. The authenticity of the amplified
product was established by hybridization of immobilized
PCR products to an internal oligonucleotide, devR1, map-
ping within the devR gene. The chromosomal DNA was
prepared by chloroform-isoamyl alcohol DNA extraction
and 4.5 µg of DNA from the isolate was restricted with
PvuII. Separation of PvuII-restricted DNA by electrophore-
sis, Southern blot hybridization with a 513-bp PCR
probes for devR (devRf, 5' GGTGAGGCGGGTTCGGTCGC
3'; devRr, 5' CGCGGCTTGCGTCCGACGTTC 3') and
chemiluminescence detection were done according to the
standard method recommended for the DNA fingerprint-
ing of M. tuberculosis [6]. Histopathologically there were
nonspecific necrosis with disintegrating polymorphs, very
few granulomatous cells and no epithelioid cells in the
biopsy specimen. USG of kidney, liver or spleen revealed
no abscess. The strain was susceptible to the 4 first line
drugs [isoniazide (H), rifampicin (R), ethambutol (E) and
pyrazinamide (Z)] by BACTEC 460TB system. Treatment
with 4-drug regimen (H = 300 mg/d, R = 450 mg/d, E =
800 mg/d and Z = 1.5 g/d) for 8 months (2EHRZ/6HR)
[7] with first 2 months supervised showed clinical
improvement.
However, the patient returned 6 months later with multi-
ple cutaneous abscesses, mainly on his back, left thigh and
left arm and miliary mottling in CXR. He denied any irreg-
ularity in antituberculosis therapy. All immunosuppres-
sive drugs (corticosteroids and methotrexate) were
discontinued as he was readmitted. Isolates from 2 of 3
consecutive sputum samples and aspirated pus samples
from all 5 completely drained abscesses were reconfirmed
as the identical M. tuberculosis strain by phage assay and
RFLP analysis (figure 1). The isolate was resistant to 4 first-
line drugs by BACTEC 460TB system and to 9 drugs, tested
into Loewenstein Jensen media (Hi-media, Mumbai,
India): H (1 µg/ml), H (10 µg/ml), R (20 µg/ml), R (50
µg/ml), E (2 µg/ml), E (10 µg/ml), Z (50 µg/ml, at pH
5.5), streptomycin (5 µg/ml), streptomycin (50 µg/ml),
paraaminosalicylate (2.5 µg/ml), cycloserine (30 µg/ml),
amikacin (700 µg/ml) and ciprofloxacin (12.5 µg/ml).
Treatment was continued with H (5 mg/kg/d), R (10 mg/
kg/d), Z (30 mg/kg/d), E (15 mg/kg/d), kanamycin (15
mg/kg IM 5 times weekly) and sparfloxacin (500 mg/d)
for 18 months with first 2 months under supervision. A
slow but complete clinical, microbiological and radiolog-
ical cure after 1.5 year was followed up for another 16
months.
Discussion
India is an endemic country for TB with an estimated
20,000 infectious cases and 1–3.3% of new cases of MDR
TB every year [8]. Infections are common with more than
one strain of M. tuberculosis during the same episode
(multiple infection), in different lesions (multiple infec-
tion) or during successive episodes (reinfection) in HIV-
positive as well as -negative individuals [9]. In this study
identical strains of M. tuberculosis were isolated at 6
months interval, but contrary to the first, the strain in the
second episode was resistant to all the first line and most
of the second line antitubercular drugs. As far as could be
ascertained, this is the first case of isolation of MDR strain
of M. tuberculosis from a HIV-negative butPage 2 of 5
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the same, but susceptible strain 6 months before.
As evident from the study, the chance of exogenous rein-
fection with the same but drug-resistant strain from some
undetected source within the endemic community is the
most likely explanation. This explains the acquisition of
resistance against all those drugs, to which the patient was
not exposed earlier. Reinfection though occurs usually
after first two to five years in immunocompetent hosts,
may progress to active disease at any time after treatment
has been discontinued and even during treatment for
active tuberculosis [10]. Moreover, an ongoing tubercu-
lous infection and simultaneous immunosuppressive
therapy might significantly divert the immune response,
thereby increasing the overall susceptibility to 'superinfec-
tion' [10] with the same but MDR strain. The chances of
'simultaneous infection' [11] with both the strains (sus-
ceptible and MDR) could be another possibility. Drug-
susceptibility testing could discriminate simultaneous
infection with different susceptibility profiles if individual
colonies from the isolate were tested whereas in our case
the sensitivity pattern of the susceptible strain might have
been obtained at first attempt. Even RFLP and phage typ-
ing were not enough to determine simultaneous infec-
tions or reinfection (superinfection).
Endogenous reactivation which is higher than the rate of
exogenous reinfection in endemic countries [12,13] with
multi- "drug resistance in previously treated case"[14]
might be a remote possibility. The history of regular med-
ication itself might be notoriously misleading in patients
with multidrug resistance [14]. However, it is difficult still
to explain the acquisition of multidrug resistance of the
The PCR amplified product for devR gene (513 bps) of M. tuberculosisFigure 1
The PCR amplified product for devR gene (513 bps) of M. tuberculosis. (From left to right) Lane M; 100 bp ladder Banglore 
Genei (India), Lane 1; Negative control, Lane 2; M. tuberculosis H37Rv, Lane 3; Patient's isolate of sensitive M. tuberculosis strain 
(on first admission), Lane 4; Patient's isolate of MDR M. tuberculosis strain (on readmission), Lane 5; M. kansasii, Lane 6; M. 
scrofulaceum.Page 3 of 5
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against those drugs, to which the patient was not exposed.
Any switch in specimens or cross-contamination of cul-
tures in laboratories were unlikely since no other sample
to switch or contaminate was identified.
Niacin test (95% positive [15]) and nitrate reduction test
(97% positive [15]) differentiated M. tuberculosis from
other mycobacteria in M. tuberculosis complex whereas
RFLP and phage typing excluded atypical mycobacteria,
like M. kansasii and M. scrofulaceum. The overall acuracy of
the drug susceptibility test ranges between 84–100%,
since mycobacteria often clump [16]. We tried thorough
vortexing with glass beads to obtain homogenous inocu-
lum suspensions.
It was a rare case of miliary TB of non-reactive type [17]
with MDR M. tuberculosis invasion of the skin without any
muscle involvement and sinus formation as the biopsy of
the axillary lymph node showed non-specific necrosis
containing disintegrating polymorphonuclear leukocytes
and enormous number of AFB. This type is more often
seen with severe HIV infection than in patients with
immunosuppressive therapy [18,19], where the liver and
the spleen are most commonly involved followed by the
lung, the bone marrow and the kidney [17], granulomas
and epithelioid cells are lacking and CXR shows incon-
spicuous diffuse mottling. In our case, there was no other
organ involvement. Moreover, the rapid skin and lung
involvement despite adequate antituberculosis therapy
suggests that the tubercle bacilli were somehow protected
from the drugs in the cutaneous and subcutaneous tissue
('paradoxical expansion of disease during therapy' [20])
either due to polymyositis-associated subcutaneous calci-
fication or due to obstruction in the small arteries with the
large mass of bacilli leading to necrosis and abscess for-
mation in the surrounding areas.
This is probably the first reported case of cure where all
first and most of the second line drugs (a total of 9 antitu-
bercular drugs) were found to be resistant. However, the
6-drug antituberculosis therapy might not be considered
as the only reason for cure, since 4 first line drugs showed
high-level resistance and chances of cross-resistance
between closely-related aminoglycosides, amikacin and
kanamycin and quinolones, sparfloxacin and cipro-
floxacin could not be ignored [21,22]. Discontinuation of
immunosuppressive therapy with a reconstitution of the
immune system and complete surgical drainage of the
abscesses might have proved to be an important adjunct
to the treatment.
Conclusions
Severe immunosuppression may lead to disseminated TB
such as miliary TB or other rare types of extra-pulmonary
TB such as cutaneous abscesses. Follow-up of patients is
important, and if response to treatment is poor, adher-
ence to treatment, drug resistance and other possible rea-
sons such as continuation of immunosuppressive therapy
should be considered. In this case intervention by drain-
age of abscesses, discontinuation of immunosuppressive
treatment and possibly long-term treatment with addi-
tional second line antituberculosis drugs eventually lead
to cure.
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